Additionally, the long data collection period involved changes in treatment models for IBD and C difficile infection, which may have influenced the results. No financial support was reported for ...

(ACXP) Monday announced that its lead antibiotic candidate, ibezapolstat, is advancing to international Phase 3 clinical trials for treating C. difficile Infection. A recent study published in the ...

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA ...

"This resistance to infection was associated with increased production of short-chain fatty acids ... between gut bacteria and colonization by C. difficile, a bacillus resistant to several ...